US · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Adaptimmune Therapeutics PLC ADAPY
11 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$178.0M
▲ 195.3% vs FY2023
EPS · FY24
$-0.05
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-275.7%
Net margin · FY24
-39.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 178.0M
Revenue, FY2024 · full 11-year series below
Revenue
Net income
The company lost 40 cents on every revenue dollar this year.
Per share
USD -0.05
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-275.7%
Return on equity, FY2024
ROE
Operating margin-38.6%
Net margin-39.8%
Return on assets-26.8%
Each USD of equity lost 276 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+175.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+207.1%
+175.5%
+33.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
1.54B
Shares outstanding, FY2024
Change, 5 years+143.4%
Change, 10 years+261.6%
The share count grew 143% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 246.0M
total assets, end of FY2024
Total assetsUSD 246.0M
EquityUSD 11.8M
CashUSD 91.1M
Gross debtUSD 50.2M
Net debtUSD -40.9M
Current ratio2.92×
The company holds more cash than debt.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2014
2013
Revenue $B
0.2
0.1
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−0.05
−0.09
−0.17
−0.17
−0.15
−0.22
−0.16
−0.13
−0.17
−0.17
−0.08
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−275.7
−187.6
−115.0
−57.8
−56.0
−74.0
−42.5
−38.0
−43.1
−16.8
−392.3
Shares out B
1.54
1.36
0.99
0.93
0.93
0.63
0.63
0.56
0.42
0.42
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed